- Home
- GFL vs RPRX Comparison
GFL vs RPRX Comparison
Compare GFL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFL
- RPRX
- Stock Information
- Founded
- GFL 2007
- RPRX 1996
- Country
- GFL Canada
- RPRX United States
- Employees
- GFL N/A
- RPRX 99
- Industry
- GFL
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- GFL
- RPRX Health Care
- Exchange
- GFL Nasdaq
- RPRX Nasdaq
- Market Cap
- GFL 17.5B
- RPRX 15.6B
- IPO Year
- GFL 2020
- RPRX 2020
- Fundamental
- Price
- GFL $50.49
- RPRX $37.58
- Analyst Decision
- GFL Strong Buy
- RPRX Strong Buy
- Analyst Count
- GFL 8
- RPRX 4
- Target Price
- GFL $57.63
- RPRX $46.75
- AVG Volume (30 Days)
- GFL 1.1M
- RPRX 2.6M
- Earning Date
- GFL 07-30-2025
- RPRX 08-06-2025
- Dividend Yield
- GFL 0.12%
- RPRX 2.34%
- EPS Growth
- GFL N/A
- RPRX 54.86
- EPS
- GFL 6.79
- RPRX 2.32
- Revenue
- GFL $5,927,221,266.00
- RPRX $2,305,243,000.00
- Revenue This Year
- GFL N/A
- RPRX $28.60
- Revenue Next Year
- GFL $6.46
- RPRX $8.07
- P/E Ratio
- GFL $7.10
- RPRX $16.19
- Revenue Growth
- GFL 19.12
- RPRX 3.02
- 52 Week Low
- GFL $38.29
- RPRX $24.05
- 52 Week High
- GFL $52.00
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- GFL 59.77
- RPRX 61.70
- Support Level
- GFL $49.43
- RPRX $36.27
- Resistance Level
- GFL $50.94
- RPRX $38.00
- Average True Range (ATR)
- GFL 0.87
- RPRX 0.73
- MACD
- GFL 0.34
- RPRX 0.01
- Stochastic Oscillator
- GFL 88.81
- RPRX 82.89
About GFL GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.